Press Releases

AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 20, 2021-- AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene

Oct 20, 2021

AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1

No adverse events or serious adverse events related to drug product in 14 patients treated in Phase 1 and 2 Fabry disease trials and Phase 1/2 Gaucher disease trial Post-gene therapy administration safety data out 4½ years for first patient dosed AVROBIO leads way with new industry-leading

Oct 19, 2021

AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress

New safety data to be reported from clinical trials in Fabry disease and Gaucher disease type 1 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today

Oct 06, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 5, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Oct 05, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Sep 03, 2021

AVROBIO to Participate at Four Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming

Sep 01, 2021

AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update

U.S. Food and Drug Administration granted Fast Track Designation to AVR-RD-04 for cystinosis Company is planning to initiate multiple registration trials in 2022 Multiple data and regulatory updates anticipated over next 12 months CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2021-- AVROBIO, Inc .

Aug 05, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Aug 04, 2021

AVROBIO to Present at Two Upcoming Investor Conferences in August

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming

Aug 02, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Jul 08, 2021



Displaying 1 - 10 of 28

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.